Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
41.07
+0.92 (2.29%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 3,226 | 2,542 | 1,367 | 775 | 28 | 234 | |
| Market Cap Growth | 179.86% | 85.99% | 76.31% | 2701.10% | -88.19% | -37.90% | |
| Enterprise Value | 2,469 | 2,212 | 1,108 | 959 | -41 | 127 | |
| Last Close Price | 41.07 | 32.76 | 23.28 | 21.52 | 11.25 | 118.75 | |
| PS Ratio | - | - | - | 874.91 | 11.88 | 12.50 | |
| PB Ratio | 5.74 | 3.55 | 2.64 | 4.21 | 0.55 | 2.79 | |
| P/TBV Ratio | 5.77 | 4.54 | 3.78 | - | 0.55 | 2.79 | |
| EV/Sales Ratio | - | - | - | 1082.03 | - | 6.78 | |
| Debt / Equity Ratio | - | - | - | - | 0.09 | 0.07 | |
| Net Debt / Equity Ratio | -1.06 | -1.06 | -1.16 | -1.84 | -1.01 | -1.04 | |
| Net Debt / EBITDA Ratio | - | - | 2.90 | 2.90 | 0.61 | 1.37 | |
| Net Debt / FCF Ratio | 4.47 | 4.47 | 3.83 | 3.40 | 0.64 | 1.62 | |
| Asset Turnover | - | - | - | 0.00 | 0.03 | 0.14 | |
| Quick Ratio | 12.94 | 12.94 | 11.16 | 10.61 | 3.83 | 4.66 | |
| Current Ratio | 13.25 | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | |
| Return on Equity (ROE) | -25.17% | -25.17% | -59.28% | -289.17% | -124.87% | -58.81% | |
| Return on Assets (ROA) | -19.80% | -19.80% | -27.43% | -35.60% | -58.53% | -30.22% | |
| Return on Capital Employed (ROCE) | -30.50% | -30.50% | -37.60% | -38.00% | -150.10% | -73.10% | |
| Earnings Yield | -3.92% | -6.11% | -15.22% | -43.70% | -302.87% | -28.09% | |
| FCF Yield | -5.25% | -6.66% | -11.52% | -12.89% | -289.74% | -23.17% | |
| Buyback Yield / Dilution | -36.21% | -36.21% | -581.85% | -104.59% | -28.19% | -23.18% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.